| Chemical Properties | Back Directory | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (207.08 mM; Need ultrasonic) | [form ]
Solid | [pka]
5.67±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
TAS1553 is a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress | [Uses]
TAS1553 is a potent, orally active protein-protein interaction (PPI) inhibitor with an IC50 values of 0.0396 μM. TAS1553 inhibits DNA replication and reduces intracellular dATP pool. TAS1553 induces apoptosis. TAS1553 can be used for cancer research[1]. | [in vivo]
TAS1553 (25-200 mg/kg; p.o.; for 24 h; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) has RNR inhibition effect in vivo[1].
TAS1553 (50-200 mg/kg; p.o.; daily, for 15 d; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) has antitumor activity in vivo[1]. | Animal Model: | Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice[1] | | Dosage: | 25, 50, 100 and 200 mg/kg | | Administration: | Oral administration; for 24hours | | Result: | Reduces intracellular dATP pool and induces the replication stress and apoptosis. |
| Animal Model: | Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice[1] | | Dosage: | 50, 100 and 200 mg/kg | | Administration: | Oral administration; daily, for 15 days | | Result: | Inhibited tumor growth in the treated group/control group (T/C) were 52.0 (50 mg/kg), 45.0 (100 mg/kg) and 29.4% (200 mg/kg), respectively. |
| [storage]
Store at -20°C | [References]
[1] Ueno H, et, al. TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress. Commun Biol. 2022 Jun 9;5(1):571. DOI:10.1038/s42003-022-03516-4 |
|
|